Medialis built the Breakthrough Cancer Pain (BTcP) market

Medialis built the Breakthrough Cancer Pain (BTcP) market

The Breakthrough Cancer Pain market is dwarfed by other pain markets, such as chronic pain.

The concept of BTcP was a relatively new one in that:

It was a specific type of cancer pain that was characterized by high intensity, short onset, short-duration pain.

Traditionally, these types of symptoms were treated with oral morphine. There was concern in the palliative care specialty that oral morphine’s pharmacokinetics were incongruent with an optimal treatment for this type of pain. Given that Oral morphine’s onset of action was around 40mins, the feeling was that the BTcP would have subsided on its own well before the oral morphine had begun to exert its effect.

Rapid onset opioids were a new class of pain medicines whose pharmacokinetic profile matched the profile of BTcP well, and was postulated to be a more efficacious option for this particular pain.

BTcP studies were difficult to complete given that high attrition rates of patients with cancer and primary research was ruled out at an early stage.


The need here was to build the BTcP market by highlighting the benefits of the ROO class. The approach adopted was to conduct a systematic review and meta analysis identifying studies where ROOs were compared to oral morphine directly, and to model expected performances of the class in a head-to-head scenario.

Strategic Asset Generation

Medialis generated the systematic review and published it in a high impact factor journal.

The article continues to be cited to this day and supports the argument to move away from oral morphine for the treatment of BTcP and to a product such as Fentanyl Buccal Tablet.
Efficacy of Rapid-Onset Oral Fentanyl Formulations vs. Oral Morphine for Cancer-Related Breakthrough Pain: A Meta-Analysis of Comparative Trials.

Jandhyala R, Fullarton JR, Bennett MI.

J Pain Symptom Manage. 2013 Feb 1. doi:pii: S0885-3924(12)00815-9. 10.1016/j.jpainsymman.2012.09.009. [Epub ahead of print]


Medialis carried out full training for the sales force and implemented 1:1 online briefings for key customers. An electronic and paper leave pieces were also produced.

The following claims were generated:

  • ~2:1 (66%) likelihood that Effentora will produce better pain relief than Abstral*
  • ~2:1 (68%) likelihood that Effentora will produce better pain relief than Actiq*
  • 2:1 (68%) likelihood that Effentora will produce better pain relief than OM*

Case Study Video

Medialis ensures the right strategic asset is generated for the right reason...communicated in the right way.

Delivering Real World Evidence... because clinical trials only get you so far.
Medialis recognises the challenges of in-house delivery of medical affairs projects, offering a complete Intelligent End-to-End Medical Affairs delivery vehicle.

case study

“The Impact of Candidate Influenza Virus and Egg-Based Manufacture on Vaccine Effectiveness”

Currently, influenza vaccine manufacturing using embryonated hen’s eggs remains the most common vaccine production method, primarily due to historical factors, the availability of supply, and lower costs.

Read More

case study

Medialis generated a strategic manuscript highlighting the importance of weight in the management of Type 2 diabetes

The client promoted a medicine for the treatment of type 2 diabetes, …

Read More

case study

Medialis successfully differentiated AZ (QW) GLP-1 within the GLP-1 class

Medialis devised a method to construct the ‘optimal’ characteristics of a GLP-1 given a range of characteristics from real products.

Read More

We use cookies to give you the best possible experience. By using our website, you're agreeing to our use of cookies. To find out more read our cookie policy